Filed with ASX · · 2 pages · English
Mesoblast Limited hosted a key opinion leader webinar discussing the use of Ryoncil as a first-line treatment after steroids for pediatric acute graft-versus-host disease. Dr. Susan Prockop from Harvard Medical School presented case studies and pivotal trial results related to Ryoncil during the webinar. The company is a leader in developing allogeneic cellular medicines for inflammatory diseases and is committed to advancing its therapies for various conditions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
USE OF RYONCIL FIRST LINE AFTER STEROIDS FOR PEDIATRIC ACUTE GRAFT VERSUS HOST DISEASE HIGHLIGHTED IN KEY OPINION LEADER WEBINAR New York, USA: November 4 and Melbourne, Australia: November 5, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for...
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast